This inventor holds 1 USPTO granted patent. Top assignee: Esteve Quimica S.a.. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Jorge Garcia Gomez: Innovator in Sigma Receptor Inhibitors
Introduction
Jorge Garcia Gomez is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of chemistry, particularly in the development of intermediates useful for synthesizing sigma receptor inhibitors. His work is characterized by a focus on innovative processes that enhance the efficiency of chemical synthesis.
Latest Patents
Jorge holds a patent for a process titled "Process for the preparation of 1-aryl-pyrazol-3-one intermediates useful in the synthesis of sigma receptors inhibitors." This invention relates to a method for preparing 1-aryl-pyrazol-3-one intermediates, tautomers, and salts thereof. The novel intermediates developed through this process are crucial for the preparation of sigma receptor inhibitors, which have potential therapeutic applications.
Career Highlights
Jorge Garcia Gomez is associated with Esteve Quimica S.A., a company known for its commitment to pharmaceutical innovation. His role at Esteve Quimica S.A. allows him to apply his expertise in chemistry to real-world applications, contributing to advancements in drug development.
Collaborations
Jorge collaborates with Martí Bartra Sanmarti, a fellow professional in the field. Their partnership exemplifies the collaborative spirit often found in research and development, where shared knowledge and expertise lead to groundbreaking innovations.
Conclusion
Jorge Garcia Gomez is a distinguished inventor whose work in the preparation of sigma receptor inhibitors showcases his innovative spirit and dedication to advancing chemical synthesis. His contributions are valuable to the pharmaceutical industry and highlight the importance of research in developing new therapeutic options.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
